---
title: "Bringspring tech.: Net loss of 2.9195 million yuan in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236817356.md"
description: "Bringspring tech. announced that the operating revenue for 2024 is 767 million yuan, a year-on-year decrease of 3.77%; the net loss attributable to shareholders of the listed company is 2.9195 million yuan, compared to a net profit of 26.5393 million yuan in the same period last year; the basic earnings per share is -0.0046 yuan/share. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital by converting reserves"
datetime: "2025-04-21T14:39:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236817356.md)
  - [en](https://longbridge.com/en/news/236817356.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236817356.md)
generator: "portal-rs"
---

# Bringspring tech.: Net loss of 2.9195 million yuan in 2024

Bringspring tech. announced that the operating revenue for 2024 is 767 million yuan, a year-on-year decrease of 3.77%; the net loss attributable to shareholders of the listed company is 2.9195 million yuan, compared to a net profit of 26.5393 million yuan in the same period last year; the basic earnings per share is -0.0046 yuan/share. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital using reserves

### Related Stocks

- [300290.CN](https://longbridge.com/en/quote/300290.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [German ambassador to Austria Cecere visits Rosenbauer Leonding plant](https://longbridge.com/en/news/296760366.md)
- [SpareBank 1 Østlandet employee share buyback offer book closes Aug. 20 at 16:00 CEST](https://longbridge.com/en/news/296449504.md)
- [Cell C publishes pro forma financials after Comm Equipment Company merger](https://longbridge.com/en/news/296585930.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**